Crossmark Global Holdings’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $200K | Buy |
+1,760
| New | +$200K | ﹤0.01% | 1277 |
|
|
2024
Q3 | – | Sell |
-7,088
| Closed | -$597K | – | 1316 |
|
|
2024
Q2 | $597K | Buy |
7,088
+85
| +1% | +$7.16K | 0.01% | 753 |
|
|
2024
Q1 | $512K | Buy |
+7,003
| New | +$512K | 0.01% | 859 |
|
|
2022
Q1 | – | Sell |
-2,706
| Closed | -$261K | – | 1367 |
|
|
2021
Q4 | $261K | Buy |
2,706
+369
| +16% | +$35.6K | 0.01% | 1217 |
|
|
2021
Q3 | $203K | Buy |
+2,337
| New | +$203K | ﹤0.01% | 1347 |
|
|
2021
Q2 | – | Sell |
-2,318
| Closed | -$220K | – | 1428 |
|
|
2021
Q1 | $220K | Buy |
+2,318
| New | +$220K | 0.01% | 1332 |
|
|
2020
Q4 | – | Sell |
-5,139
| Closed | -$306K | – | 1413 |
|
|
2020
Q3 | $306K | Sell |
5,139
-177
| -3% | -$10.5K | 0.01% | 1012 |
|
|
2020
Q2 | $371K | Buy |
5,316
+113
| +2% | +$7.89K | 0.01% | 894 |
|
|
2020
Q1 | $236K | Sell |
5,203
-80
| -2% | -$3.63K | 0.01% | 978 |
|
|
2019
Q4 | $344K | Buy |
5,283
+1,394
| +36% | +$90.8K | 0.01% | 1031 |
|
|
2019
Q3 | $241K | Sell |
3,889
-240
| -6% | -$14.9K | 0.01% | 1173 |
|
|
2019
Q2 | $294K | Sell |
4,129
-454
| -10% | -$32.3K | 0.01% | 1113 |
|
|
2019
Q1 | $359K | Buy |
4,583
+32
| +0.7% | +$2.51K | 0.01% | 1019 |
|
|
2018
Q4 | $385K | Sell |
4,551
-513
| -10% | -$43.4K | 0.01% | 899 |
|
|
2018
Q3 | $867K | Sell |
5,064
-335
| -6% | -$57.4K | 0.02% | 666 |
|
|
2018
Q2 | $698K | Buy |
5,399
+260
| +5% | +$33.6K | 0.02% | 752 |
|
|
2018
Q1 | $530K | Sell |
5,139
-257
| -5% | -$26.5K | 0.01% | 885 |
|
|
2017
Q4 | $461K | Buy |
5,396
+390
| +8% | +$33.3K | 0.01% | 1055 |
|
|
2017
Q3 | $425K | Buy |
+5,006
| New | +$425K | 0.01% | 1070 |
|
|
2016
Q3 | $425K | Buy |
+5,006
| New | +$425K | 0.01% | 1070 |
|